tibolon aristo 25mg - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

xyvion tibolone 2.5mg tablet blister pack

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; ascorbyl palmitate; potato starch; lactose monohydrate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, xyvion should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). xyvion should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

tibolone lupin tibolone 2.5 mg tablet blister pack

southern cross pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: mannitol; lactose monohydrate; magnesium stearate; potato starch; ascorbyl palmitate - - short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,- second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.